Bicara Therapeutics Inc. Common Stock (BCAX) Stock Ticker
BCAX right now
Market factors today
Unlock the full BCAX picture
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
BCAX stock facts
| Ticker symbol | BCAX |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.3B |
| CEO | Claire Mazumdar Clemon |
| Employees | 103 |
| Headquarters | Boston, MA, US |
| IPO date | 2024-09-13 |
| Website | www.bicara.com |
What you can see for BCAX on Tickr
Live BCAX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the BCAX report.
Rankings
FAQ
What is the ticker symbol for Bicara Therapeutics Inc. Common Stock?
The ticker symbol for Bicara Therapeutics Inc. Common Stock is BCAX, listed on the NASDAQ Global Market.
What is BCAX?
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent…